Indications and practice of diverting ileostomy after colorectal resection and anastomosis in ovarian cancer cytoreduction.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
09 2020
Historique:
received: 11 04 2020
accepted: 27 05 2020
pubmed: 24 6 2020
medline: 16 4 2021
entrez: 24 6 2020
Statut: ppublish

Résumé

To determine the factors related with diverting ileostomy performance after colorectal resection and anastomosis, in advanced ovarian cancer cytoreductive surgery. We have previously demonstrated the risk factors associated with anastomotic leak after colorectal anastomosis: Advanced age at surgery, low serum albumin level, additional bowel resections, manual anastomosis and distance of the anastomosis from the anal verge. However, use of diverting ileostomy is strongly variable and depends on individual surgeon preferences and training. Eight hospitals participated in this retrospective study. Data of 695 patients operated for ovarian cancer with primary colorectal anastomosis were included (January 2010-June 2018). Fourteen pre-/intraoperatively defined variables were identified and analysed as justification factors for use of diverting ileostomy. The rate of diverting ileostomy in the entire cohort was 19.13% (133/695; range within individual centers 4.6-24.32%). Previous treatment with bevacizumab [OR 2.8 (1.3-6.1); p=0.01]; additional bowel resections [OR 3.0 (1.8-5.1); p<0.001]; extended operating time [OR 1.005 (1.003-1.006); p<0.001] and intra-operative red blood transfusion [OR 2.7 (1.4-5.3); p<0.001] were found to be independently associated with diverting ileostomy performance. Assuming a 7% AL rate cut-off, up to 51.8% of DI presented an AL risk below 7% and might have been spared. The risk factors that drive the gynecologic oncology surgeons to perform a diverting ileostomy, seem to differ from the actual risk factors that we have identified to be associated with postoperative anastomotic leak. Broader awareness of the risk factors that contribute to a higher perioperative risk profile, will facilitate a better risk stratification process and possibly avoid unnecessary stoma formation in ovarian cancer patients.

Identifiants

pubmed: 32571682
pii: S0090-8258(20)31132-X
doi: 10.1016/j.ygyno.2020.05.047
pii:
doi:

Substances chimiques

Bevacizumab 2S9ZZM9Q9V

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

603-607

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

V Lago (V)

Department of Gynecologic Oncology, University Hospital La Fe, Valencia, Spain. Electronic address: victor.lago.leal@hotmail.com.

C Fotopoulou (C)

Department of Gynecologic Oncology, Imperial College London, London, United Kingdom.

V Chiantera (V)

Department of Gynecologic Oncology, University of Palermo, Palermo, Italy.

L Minig (L)

Department of Gynecology, CEU Cardenal Herrera University, Valencia, Spain.

A Gil-Moreno (A)

Department of Obstetrics and Gynecology, Vall d'Hebron University Hospital, Barcelona, Spain.

P A Cascales-Campos (PA)

Department of General Surgery, Virgen de la Arrixaca Clinic and University Hospital, Murcia, Spain.

M Jurado (M)

Department of Obstetrics and Gynecology, University Clinic of Navarra, Madrid and Navarre, Spain.

A Tejerizo (A)

Department of Obstetrics and Gynecology, Hospital 12 de Octubre, Madrid, Spain.

P Padilla-Iserte (P)

Department of Gynecologic Oncology, University Hospital La Fe, Valencia, Spain.

M E Malune (ME)

Department of Gynecologic Oncology, Imperial College London, London, United Kingdom.

M C Di Donna (MC)

Department of Gynecologic Oncology, University of Palermo, Palermo, Italy.

T Marina (T)

Department of Gynecologic Oncology, University Hospital La Fe, Valencia, Spain.

J L Sanchez-Iglesias (JL)

Department of Obstetrics and Gynecology, Vall d'Hebron University Hospital, Barcelona, Spain.

L Chiva (L)

Department of Obstetrics and Gynecology, University Clinic of Navarra, Madrid and Navarre, Spain.

A Olloqui (A)

Department of Obstetrics and Gynecology, Hospital 12 de Octubre, Madrid, Spain.

L Matute (L)

Department of Gynecologic Oncology, University Hospital La Fe, Valencia, Spain.

A García-Granero (A)

Department of General Surgery, University Hospital Son Espases, Palma de Mallorca, Spain; Department of Human Embryology and Anatomy, University of Valencia, Valencia, Spain.

J M Cárdenas-Rebollo (JM)

Department of Applied Mathematics and Statistics, CEU San Pablo University, Madrid, Valencia, Spain.

S Domingo (S)

Department of Gynecologic Oncology, University Hospital La Fe, Valencia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH